This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


Rimantadine

From Proteopedia

Revision as of 12:30, 6 December 2010 by David Canner (Talk | contribs)
Jump to: navigation, search

Rimantadine, also known as Flumadine

Drag the structure with the mouse to rotate

Better Known as: Flumadine

  • Marketed By: Forest Labs
  • Major Indication: Influenza Infection
  • Drug Class: M2 Proton Channel Inhibitor
  • Date of FDA Approval (Patent Expiration): 1993 (2001)
  • 1994 Sales: N/A
  • Importance: One of the the first treatments for Influenza Infections. Since 1994, nearly 100% of influenza viruses had developed resistance to rimantadine, and it is no longer recommended as a treatment for the flu.
  • The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information

Mechanism of Action

Pharmacokinetics

M2 Proton Channel Inhibitor Pharmacokinetics[1]
Parameter Rimantadine Amantadine
Tmax (hr) 4.3 Amantadine
Cmax (ng/ml) 310 Amantadine
Bioavailability (%) >90 >90
Protein Binding (%) 40 67
T1/2 (hr) 27.7 ~15
AUC (ng/ml/hr) 11917 Amantadine
Clearance (L/h) Rimantadine Amantadine
Dosage (mg) 100 Amantadine
Metabolism Rimantadine Amantadine

References

  1. ↑ Anderson EL, Van Voris LP, Bartram J, Hoffman HE, Belshe RB. Pharmacokinetics of a single dose of rimantadine in young adults and children. Antimicrob Agents Chemother. 1987 Jul;31(7):1140-2. PMID:3662473


Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky

Retrieved from "http://52.214.119.220/wiki/index.php/Rimantadine"
Personal tools